VEGFA and wet macular degeneration: Given the importance of the pro-angiogenic pathway downstream of VEGF, inhibiting the VEGF signaling axis has proven an effective therapy for patients with solid tumors and neovascular age-related macular degeneration; drugs such as bevacizumab and aflibercept which sequester circulating VEGF have shown efficacy in some of these clinical situations [1, 2].